CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Feraheme +1 moredrug
Likely dose
Feraheme 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01336803
NCT01336803Phase 2Completed
CompareCT.gov

Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Heike E Daldrup-Link·interventional·Posted Apr 18, 2011·Updated Dec 27, 2023

In Brief

A Phase 2 clinical trial evaluating Feraheme and Magnetic Resonance Imaging (MRI) scan for Bone Cancer and 7 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Cancer, Chondrosarcoma, Ewing's Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Bone Necrosis, Bone Sarcoma, Osteomyelitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 18, 2011
Enrollment StartAug 1, 2011
Primary CompletionJul 1, 2014
Study CompletionOct 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.2 years ago

Interventions

Ferahemedrug

5 mg/kg by intravenous (IV) administration

Magnetic Resonance Imaging (MRI) scanprocedure

Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/